Latest Period
Q4 2025
Security Snapshot
Viking Therapeutics, Inc. - Common Stock (VKTX) Institutional Ownership
CUSIP: 92686J106
13F Institutional Holders and Ownership History from Q2 2015 to Q1 2026
Institutions Reporting
416
Shares (Excl. Options)
71,856,661
Price
$35.18
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock
- Symbol
- VKTX on Nasdaq
- Shares outstanding
- 115,694,154
- Price per share
- $34.95
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 71,856,661
- Total reported value
- $2,527,921,428
- % of total 13F portfolios
- 0.01%
- Share change
- -959,273
- Value change
- -$5,880,372
- Number of holders
- 416
- Price from insider filings
- $34.95
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- VKTX - Viking Therapeutics, Inc. - Common Stock is tracked under CUSIP 92686J106.
- 416 institutions reported positions in Q4 2025.
- 3 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 416 to 162 between Q4 2025 and Q1 2026.
- Reported value moved from $2,527,921,428 to $234,201,240.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 416 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 92686J106?
CUSIP 92686J106 identifies VKTX - Viking Therapeutics, Inc. - Common Stock in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 92686J106:
Significant Owners of Viking Therapeutics, Inc. - Common Stock (VKTX) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | 5.1% | $191,246,138 | 5,877,263 | Vanguard Capital Management | 31 Mar 2026 | |||
| FMR LLC | 5.1% | -40% | $151,689,488 | -$105,010,859 | 5,772,051 | -41% | FMR LLC | 30 Sep 2025 |
| BlackRock, Inc. | 4.5% | -16% | $140,580,417 | -$23,501,200 | 5,031,511 | -14% | BlackRock, Inc. | 31 Mar 2025 |
As of 31 Dec 2025, 416 institutional investors reported holding 71,856,661 shares of Viking Therapeutics, Inc. - Common Stock (VKTX). This represents 62% of the company’s total 115,694,154 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Viking Therapeutics, Inc. - Common Stock (VKTX) together control 46% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| VANGUARD GROUP INC | 8.6% | 9,984,487 | -0.15% | 0.01% | $351,254,252 |
| BlackRock, Inc. | 5.7% | 6,611,874 | +18% | 0% | $232,605,730 |
| FMR LLC | 5.7% | 6,557,766 | +13% | 0.01% | $230,702,223 |
| STATE STREET CORP | 3.8% | 4,445,430 | -1.5% | 0.01% | $156,390,227 |
| MORGAN STANLEY | 2.7% | 3,076,270 | -18% | 0.01% | $108,223,187 |
| TWO SIGMA INVESTMENTS, LP | 2.1% | 2,435,737 | +17% | 0.13% | $85,689,228 |
| TWO SIGMA ADVISERS, LP | 1.8% | 2,129,228 | +37% | 0.15% | $74,906,241 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.7% | 1,994,509 | +24% | 0% | $70,182,515 |
| CITADEL ADVISORS LLC | 1.5% | 1,732,421 | -8.7% | 0.04% | $60,946,570 |
| D. E. Shaw & Co., Inc. | 1.5% | 1,718,493 | +965% | 0.05% | $60,456,584 |
| JANE STREET GROUP, LLC | 1.3% | 1,501,117 | +89% | 0.06% | $52,809,297 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1.2% | 1,423,831 | -32% | 0.07% | $50,090,375 |
| AMERIPRISE FINANCIAL INC | 1.2% | 1,339,104 | -36% | 0.01% | $47,109,681 |
| BNP PARIBAS FINANCIAL MARKETS | 0.86% | 992,695 | 0% | 0.02% | $34,923,010 |
| UBS Group AG | 0.81% | 934,925 | -30% | 0.01% | $32,890,662 |
| RAYMOND JAMES FINANCIAL INC | 0.8% | 921,998 | -3.4% | 0.01% | $32,435,889 |
| GOLDMAN SACHS GROUP INC | 0.72% | 832,651 | +211% | 0% | $29,292,662 |
| Pictet Asset Management Holding SA | 0.65% | 752,732 | -37% | 0.03% | $26,481,112 |
| ExodusPoint Capital Management, LP | 0.62% | 722,199 | +254% | 0.28% | $25,406,961 |
| Artia Global Partners LP | 0.62% | 719,365 | +392% | 4.1% | $25,307,261 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.61% | 700,295 | +0.37% | 0% | $24,636,378 |
| BlackBarn Capital Partners LP | 0.48% | 550,000 | +10% | 6.9% | $19,349,000 |
| JPMORGAN CHASE & CO | 0.47% | 546,828 | -79% | 0% | $19,237,409 |
| NORTHERN TRUST CORP | 0.47% | 541,054 | -2.9% | 0% | $19,034,280 |
| Connor, Clark & Lunn Investment Management Ltd. | 0.45% | 518,796 | -4.7% | 0.05% | $18,251,243 |
Institutional Holders of Viking Therapeutics, Inc. - Common Stock (VKTX) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 7,195,322 | $234,201,240 | +$17,001,154 | $32.54 | 162 |
| 2025 Q4 | 71,856,661 | $2,527,921,428 | -$5,880,372 | $35.18 | 416 |
| 2025 Q3 | 71,269,115 | $1,872,831,260 | -$129,887,705 | $26.28 | 366 |
| 2025 Q2 | 76,160,666 | $2,018,412,050 | +$15,581,298 | $26.50 | 386 |
| 2025 Q1 | 76,178,049 | $1,840,349,819 | -$233,469,532 | $24.15 | 365 |
| 2024 Q4 | 82,015,393 | $3,300,204,748 | -$139,093,256 | $40.24 | 405 |
| 2024 Q3 | 82,930,091 | $5,250,281,341 | +$233,179,536 | $63.31 | 418 |
| 2024 Q2 | 80,417,324 | $4,262,902,509 | -$169,985,696 | $53.01 | 383 |
| 2024 Q1 | 80,009,652 | $6,559,940,568 | +$370,099,401 | $82.00 | 365 |
| 2023 Q4 | 76,419,206 | $1,422,250,248 | +$18,477,372 | $18.61 | 193 |
| 2023 Q3 | 77,149,919 | $854,043,342 | +$8,950,047 | $11.07 | 176 |
| 2023 Q2 | 74,791,312 | $1,212,232,718 | +$127,119,937 | $16.21 | 192 |
| 2023 Q1 | 66,472,048 | $1,107,025,988 | +$548,273,938 | $16.65 | 183 |
| 2022 Q4 | 34,003,932 | $319,613,212 | +$76,425,883 | $9.40 | 126 |
| 2022 Q3 | 26,578,143 | $72,293,762 | -$1,008,538 | $2.72 | 95 |
| 2022 Q2 | 26,701,115 | $77,182,300 | -$11,574,558 | $2.89 | 97 |
| 2022 Q1 | 31,036,457 | $93,177,398 | -$16,601,086 | $3.00 | 131 |
| 2021 Q4 | 36,199,999 | $166,471,159 | -$8,903,915 | $4.60 | 133 |
| 2021 Q3 | 37,764,404 | $237,662,655 | -$338,194 | $6.28 | 125 |
| 2021 Q2 | 37,867,341 | $226,858,479 | -$19,626,288 | $5.99 | 133 |
| 2021 Q1 | 41,005,365 | $259,319,860 | +$20,962,700 | $6.32 | 137 |
| 2020 Q4 | 37,734,744 | $212,602,882 | -$11,096,629 | $5.63 | 136 |
| 2020 Q3 | 39,564,196 | $230,268,043 | -$4,355,775 | $5.82 | 139 |
| 2020 Q2 | 40,230,477 | $290,007,852 | +$8,150,488 | $7.21 | 133 |
| 2020 Q1 | 39,356,943 | $184,161,493 | -$8,373,431 | $4.68 | 130 |
| 2019 Q4 | 39,771,461 | $318,974,059 | -$5,272,426 | $8.02 | 134 |
| 2019 Q3 | 40,703,230 | $280,039,135 | -$33,395,341 | $6.88 | 139 |
| 2019 Q2 | 45,087,675 | $374,231,879 | -$7,341,449 | $8.30 | 150 |
| 2019 Q1 | 45,718,634 | $454,329,676 | -$4,966,661 | $9.94 | 158 |
| 2018 Q4 | 46,936,233 | $359,030,721 | -$11,223,062 | $7.65 | 159 |
| 2018 Q3 | 43,213,947 | $752,787,195 | +$280,535,030 | $17.42 | 146 |
| 2018 Q2 | 31,601,829 | $299,901,220 | +$126,057,321 | $9.49 | 115 |
| 2018 Q1 | 20,905,622 | $91,354,000 | +$50,569,356 | $4.37 | 62 |
| 2017 Q4 | 9,329,591 | $37,876,000 | +$30,074,098 | $4.06 | 32 |
| 2017 Q3 | 2,021,286 | $3,851,000 | +$1,491,357 | $1.91 | 16 |
| 2017 Q2 | 1,568,425 | $1,692,000 | +$856,257 | $1.08 | 11 |
| 2017 Q1 | 769,601 | $1,124,000 | +$226,915 | $1.46 | 10 |
| 2016 Q4 | 636,030 | $757,000 | -$869,302 | $1.19 | 11 |
| 2016 Q3 | 1,209,905 | $1,701,000 | +$495,636 | $1.41 | 13 |
| 2016 Q2 | 860,090 | $1,083,000 | +$1,026,020 | $1.26 | 12 |
| 2016 Q1 | 44,443 | $65,000 | -$25,998 | $1.53 | 6 |
| 2015 Q4 | 41,278 | $140,000 | -$14,614 | $3.36 | 5 |
| 2015 Q3 | 43,175 | $252,000 | -$77,596 | $5.83 | 6 |
| 2015 Q2 | 54,005 | $384,000 | +$384,000 | $7.10 | 5 |